The accelerated aging model reveals critical mechanisms of late-onset Parkinson’s disease

Background Late-onset Parkinson’s disease (LOPD) is a common neurodegenerative disorder and lacks disease-modifying treatments, attracting major attentions as the aggravating trend of aging population. There were numerous evidences supported that accelerated aging was the primary risk factor for LOPD, thus pointed out that the mechanisms of PD should be revealed thoroughly based on aging acceleration. However, how PD was triggered by accelerated aging remained unclear and the systematic prediction model was needed to study the mechanisms of PD. Results In this paper, an improved PD predictor was presented by comparing with the normal aging process, and both aging and PD markers were identified herein using machine learning methods. Based on the aging scores, the aging acceleration network was constructed thereby, where the enrichment analysis shed light on key characteristics of LOPD. As a result, dysregulated energy metabolisms, the cell apoptosis, neuroinflammation and the ion imbalances were identified as crucial factors linking accelerated aging and PD coordinately, along with dysfunctions in the immune system. Conclusions In short, mechanisms between aging and LOPD were integrated by our computational pipeline.

[1]  F. Sesti,et al.  Oxidation of ion channels in the aging nervous system , 2016, Brain Research.

[2]  Susan M. Resnick,et al.  Morphometry of the human substantia nigra in ageing and Parkinson’s disease , 2008, Acta Neuropathologica.

[3]  B. Cheeran,et al.  Parkinson's Disease: New Insights into Pathophysiology and Rehabilitative Approaches , 2016, Parkinson's disease.

[4]  H. Tian,et al.  Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1. , 2012, Molecular endocrinology.

[5]  Y. Higami,et al.  Apoptosis in the aging process , 2000, Cell and Tissue Research.

[6]  Andrew J. Oler,et al.  Bcl11b, a novel GATA3-interacting protein, suppresses Th1 while limiting Th2 cell differentiation , 2018, The Journal of experimental medicine.

[7]  T. Wyss-Coray,et al.  Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration , 2020, Nature Reviews Neuroscience.

[8]  I. Ekimova,et al.  Parkinson’s Disease and Aging , 2019, Advances in Gerontology.

[9]  Adducin family proteins possess different nuclear export potentials , 2017, Journal of Biomedical Science.

[10]  J. Kordower,et al.  Aging and Parkinson’s Disease: Different Sides of the Same Coin? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[11]  R. Takahashi,et al.  ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease , 2017, EBioMedicine.

[12]  S. Mallal,et al.  T cells of Parkinson’s disease patients recognize α–synuclein peptides , 2017, Nature.

[13]  M. Maggiolini,et al.  The Physiopathological Role of the Exchangers Belonging to the SLC37 Family , 2018, Front. Chem..

[14]  Salim Lahmiri,et al.  Gait Nonlinear Patterns Related to Parkinson’s Disease and Age , 2019, IEEE Transactions on Instrumentation and Measurement.

[15]  J. Fernández-Ruiz,et al.  Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease , 2019, Molecules.

[16]  B. Liss,et al.  Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease , 2016, Journal of neurochemistry.

[17]  P. Aebischer,et al.  Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease , 2015, Biomolecules.

[18]  M. Vila,et al.  Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows , 2019, Cells.

[19]  Ryan J. Uitti,et al.  Biomarkers in Parkinson's disease: Advances and strategies. , 2016, Parkinsonism & related disorders.

[20]  PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s , 2014, Neurochemical Research.

[21]  C. Franceschi,et al.  Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis , 2018, Free radical biology & medicine.

[22]  B. Brew,et al.  Bcl11b—A Critical Neurodevelopmental Transcription Factor—Roles in Health and Disease , 2017, Front. Cell. Neurosci..

[23]  B. Hayete,et al.  Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation , 2017, The Lancet Neurology.

[24]  S. Zanata,et al.  PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease , 2019, Pharmacological reports : PR.

[25]  G. Halliday,et al.  Inflammation is genetically implicated in Parkinson’s disease , 2015, Neuroscience.

[26]  Robert Howard,et al.  A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status , 2015, Genome Biology.

[27]  J. Kirkland,et al.  Cellular Senescence: A Translational Perspective , 2017, EBioMedicine.

[28]  M. Mattson,et al.  Brain metabolism in health, aging, and neurodegeneration , 2017, The EMBO journal.

[29]  R. Thangavel,et al.  Neuroinflammation Induces Neurodegeneration. , 2016, Journal of neurology, neurosurgery and spine.

[30]  P. Rosenstiel,et al.  Linear isoforms of the long noncoding RNA CDKN2B-AS1 regulate the c-myc-enhancer binding factor RBMS1 , 2018, European Journal of Human Genetics.

[31]  S. Maier,et al.  Aging-related changes in neuroimmune-endocrine function: Implications for hippocampal-dependent cognition , 2012, Hormones and Behavior.

[32]  Amir Shmuel,et al.  Performance of machine learning methods in diagnosing Parkinson’s disease based on dysphonia measures , 2017, Biomedical Engineering Letters.

[33]  Ying Wang,et al.  PPAR signaling pathway in the first trimester placenta from in vitro fertilization and embryo transfer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[34]  J. Błaszczyk The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease , 2018, Front. Aging Neurosci..

[35]  T. Strom,et al.  BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells , 2018, Brain : a journal of neurology.

[36]  Linnan Zhu,et al.  Impact of aging immune system on neurodegeneration and potential immunotherapies , 2017, Progress in Neurobiology.

[37]  V. Kostulas,et al.  Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood , 1994, Acta neurologica Scandinavica.

[38]  V. Appay,et al.  Aging of the immune system: Focus on inflammation and vaccination , 2016, European journal of immunology.

[39]  M. Beal,et al.  PPAR: a therapeutic target in Parkinson’s disease , 2008, Journal of neurochemistry.

[40]  A. Abramov,et al.  Mitochondrial calcium imbalance in Parkinson’s disease , 2017, Neuroscience Letters.

[41]  A. Chawla,et al.  BCL6 regulates brown adipocyte dormancy to maintain thermogenic reserve and fitness , 2019, Proceedings of the National Academy of Sciences.

[42]  Amir Shmuel,et al.  Detection of Parkinson's disease based on voice patterns ranking and optimized support vector machine , 2019, Biomed. Signal Process. Control..

[43]  G. Leung,et al.  A Review on Adducin from Functional to Pathological Mechanisms: Future Direction in Cancer , 2018, BioMed research international.

[44]  M. Cano,et al.  Advantages and disadvantages of apoptosis in the aging process , 2019, Annals of the New York Academy of Sciences.

[45]  A. Carta PPAR-γ: therapeutic prospects in Parkinson's disease. , 2013, Current drug targets.

[46]  S. Mallal,et al.  T cells of Parkinson’s disease patients recognize α–synuclein peptides , 2017, Nature.